col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


52 Results       Page 1

 [1] 
American Chemical Society: ACS Medicinal Chemistry Letters
  original article Date Title Authors   All Authors
1 [GO] 2026―Jun―09 Novel Compounds as SARS-CoV-2 Main Protease Inhibitors for Treating Viral Infections, in particular, Coronavirus Infections Ram W. Sabnis
2 [GO] 2026―May―06 Novel Competitive, Nonpeptidic, SARS-CoV-2 M pro Inhibitors with Improved Solubility Zafer Sahin, Mario Rivera, Yanli Yang, Ken Liu, Goknil P. C. Sahin, John Bacsa, et al. (+2)
3 [GO] 2026―Mar―04 Ugi-Tetrazole-Derived α-Aminomethyl Scaffolds Reveal Unexpected Binding Modes in SARS-CoV-2 3CLpro Robin van der Straat, Rick Oerlemans, Yingying Cong, Jeffrey Boxma, Radu G. Bulai, Clàudia Río-Bergé, et al. (+7)
4 [GO] 2025―Oct―30 Targeting the S1′ Pocket of SARS-CoV-2 Papain-Like Protease Yields Highly Potent Inhibitors Dnyaneshwar N. Garad, Xin Li, Teck Khiang Chua, Bala Krishna Moku, Chandra Bhushan Mishra, Yongcheng Song
5 [GO] 2025―Sep―25 Identification and Exploration of a Series of SARS-Cov-2 MPro Cyano-Based Inhibitors Revealing Ortho-Substitution Effects within the P3 Biphenyl Group Emma Clyde-Allen, Mikołaj Zmudzinski, Mohammad Afsar, Ciyana James, Anindita Nayak, Digant Nayak, et al. (+7)
6 [GO] 2025―Sep―16 Structure-Guided Temporin L Analogs Development to Inhibit the Main Protease of SARS-CoV-2 James Stewart, Ruoqing Jia, Md Ackas Ali, Blaise Williams, Kaylee Stone, Ryan Faddis, et al. (+4)
7 [GO] 2025―Sep―05 Design and Synthesis of Pyrazoline Inhibitors of SARS-CoV-2 NSP14 Elliott B. Smyth, João P. Pisco, Kristian Birchall, Nicole S. Upfold, Arvind H. Patel, Richard Foster, Jonathan M. Large
8 [GO] 2025―Aug―15 Discovery of Novel Isofunctional SARS-CoV-2 NSP14 RNA Cap Methyltransferase Inhibitors by Structure-Based Virtual Screening Cindy Meyer, Mayako Michino, David J. Huggins, Aitor Garzia, Jada A. Davis, Michael W. Miller, et al. (+9)
9 [GO] 2025―Apr―14 Design, Synthesis, and Biological Evaluation of Peptidomimetic Tetrahydropyrrole Spirodihydroindolones as SARS-CoV-2 3CL Protease Inhibitors Liuyan Hu, Zhi Zhao, Shujing Zhang, Lei Yang, Wenjie Cui, Tianwen Hu, et al. (+10)
10 [GO] 2025―Mar―17 Design, Synthesis, Evaluation, and Molecular Dynamics Simulation of SARS-CoV-2 Mpro Inhibitors Qinghua Yang, Keli Zong, Xu Zhao, Fenghua Zhang, Fei Li, Xingzhou Li
11 [GO] 2024―Dec―02 Discovery of Non-Covalent Inhibitors for SARS-CoV-2 PLpro: Integrating Virtual Screening, Synthesis, and Experimental Validation Bruna K. P. Sousa, Melina Mottin, Donald Seanego, Christopher D. Jurisch, Beatriz S. A. Rodrigues, Verônica L. S. da Silva, et al. (+10)
12 [GO] 2024―Nov―15 Pyrrolidines as Main Protease Inhibitors for Treating Viral Infections, in Particular, Coronavirus Infections Ram W. Sabnis
13 [GO] 2024―Nov―03 Peptide Aldehydes Incorporating Thiazol-4-yl Alanine Are Potent In Vitro Inhibitors of SARS-CoV-2 Main Protease Jenson R. Feys, Kyle Edwards, Michael A. Joyce, Holly A. Saffran, Justin A. Shields, Kassandra Garcia, et al. (+2)
14 [GO] 2024―Oct―15 Novel Papain-Like Protease Inhibitors for Treating Viral Infections, in Particular Coronavirus Infections Ram W. Sabnis
15 [GO] 2024―Jul―23 Novel Papain-Like Protease Inhibitors for Treating Viral Infections, in particular, Coronavirus Infections Ram W. Sabnis
16 [GO] 2024―Jul―23 Fragment-Based Screen of SARS-CoV-2 Papain-like Protease (PLpro) Ashley J. Taylor, Kangsa Amporndanai, Tyson A. Rietz, Bin Zhao, Anusha Thiruvaipati, Qiangqiang Wei, et al. (+7)
17 [GO] 2024―May―20 SARS-CoV-2 Main Protease Inhibitors That Leverage Unique Interactions with the Solvent Exposed S3 Site of the Enzyme Lauren R. Blankenship, Kai S. Yang, Veerabhadra R. Vulupala, Yugendar R. Alugubelli, Kaustav Khatua, Demonta Coleman, et al. (+7)
18 [GO] 2024―Mar―14 Chemical Space Profiling of SARS-CoV-2 PLpro Using DNA-Encoded Focused Libraries Xudong Wang, Ying Zhu, Qingyi Zhao, Weiwei Lu, Yechun Xu, Hangchen Hu, Xiaojie Lu
19 [GO] 2024―Jan―10 Development of a GC-376 Based Peptidomimetic PROTAC as a Degrader of 3-Chymotrypsin-like Protease of SARS-CoV-2 Deborah Grifagni, Elena Lenci, Alessia De Santis, Andrea Orsetti, Carlo Giorgio Barracchia, Filomena Tedesco, et al. (+10)
20 [GO] 2023―Nov―20 Conformationally Restricted Analogues of α-Galactosylceramide as Adjuvant in COVID-19 Subunit Vaccine Xing Hu, Mao-Ying Xian, Xi-Feng Wang, Guo-Qing Zou, Rui Luo, Hao Peng, Zheng Liu
21 [GO] 2023―Oct―06 Protease Inhibitors for Treating or Preventing Coronavirus Infection Ram W. Sabnis
22 [GO] 2023―Sep―29 Heparan Sulfate-Mimicking Glycopolymers Bind SARS-CoV-2 Spike Protein in a Length- and Sulfation Pattern-Dependent Manner Hawau Abdulsalam, Jiayi Li, Ravi S. Loka, Eric T. Sletten, Hien M. Nguyen
23 [GO] 2023―Sep―28 Design and Optimization of Novel Competitive, Non-peptidic, SARS-CoV-2 Mpro Inhibitors Leon Jacobs, Aletta van der Westhuyzen, Nicole Pribut, Zackery W. Dentmon, Dan Cui, Michael P. D’Erasmo, et al. (+15)
24 [GO] 2023―Aug―10 Novel Compounds for Preventing SARS-CoV-2 Viral Replication and Treating COVID-19 Ram W. Sabnis
25 [GO] 2023―May―11 Discovery of Small Molecules Targeting the Frameshifting Element RNA in SARS-CoV-2 Viral Genome Mo Yang, Feyisola P. Olatunji, Curran Rhodes, Sumirtha Balaratnam, Kara Dunne-Dombrink, Srinath Seshadri, et al. (+5)
26 [GO] 2022―Aug―19 Oral Nonpeptidic, Noncovalent Triazine Coronavirus Main Protease Inhibitors for Treating COVID-19 C. S. Brian Chia, Masafumi Inoue
27 [GO] 2022―Aug―08 Novel Coronavirus Main Protease Di- and Tripeptide Inhibitors for Treating COVID-19 C. S. Brian Chia, Yi Yang See
28 [GO] 2022―Jul―22 Bisubstate Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 Nsp14 Methyltransferase Eunkyung Jung, Ruben Soto-Acosta, Jiashu Xie, Daniel J. Wilson, Christine D. Dreis, Ryuichi Majima, et al. (+3)
29 [GO] 2022―Jul―19 A Warhead Substitution Study on the Coronavirus Main Protease Inhibitor Nirmatrelvir Subramanyam Vankadara, Monique Danielle Dawson, Jia Yi Fong, Qin Yao Oh, Qi An Ang, Boping Liu, et al. (+6)
30 [GO] 2022―Jun―06 SARS-CoV-2: Novel Therapeutic Approaches for Diagnosis and Treatment Robert B. Kargbo
31 [GO] 2022―May―27 Novel Halomethylketone Azadipeptides for Treating COVID-19 C. S. Brian Chia, Yi Yang See
32 [GO] 2022―Mar―25 How a Blockchain Approach Can Improve Data Reliability in the COVID-19 Pandemic Pietro Cozzini, Federica Agosta, Greta Dolcetti, Gianfranco Righi
33 [GO] 2022―Feb―21 Phosphoramidate Prodrugs Continue to Deliver, The Journey of Remdesivir (GS-5734) from RSV to SARS-CoV-2 Richard L. Mackman
34 [GO] 2022―Feb―03 Novel Nitrile Peptidomimetics for Treating COVID-19 C. S. Brian Chia
35 [GO] 2021―Nov―18 Novel Compounds for Preventing SARS-CoV-2 Viral Replication and Treating COVID-19 Ram W. Sabnis
36 [GO] 2021―Oct―13 Expression of Concern for “Molecular Biology Clues Portray SARS-CoV-2 as a Gain-of-Function Laboratory Manipulation of Bat CoV RaTG13” Dennis Liotta
37 [GO] 2021―Oct―09 On the Selectivity of Heparan Sulfate Recognition by SARS-CoV-2 Spike Glycoprotein John E. Chittum, Nehru Viji Sankaranarayanan, Connor P. O’Hara, Umesh R. Desai
38 [GO] 2021―Sep―29 Design and Evaluation of Bispidine-Based SARS-CoV-2 Main Protease Inhibitors Dmitriy Shcherbakov, Dmitriy Baev, Mikhail Kalinin, Alexander Dalinger, Varvara Chirkova, Svetlana Belenkaya, et al. (+11)
39 [GO] 2021―Jul―28 Discovery of Small Molecule Entry Inhibitors Targeting the Fusion Peptide of SARS-CoV-2 Spike Protein Xin Hu, Catherine Z. Chen, Miao Xu, Zongyi Hu, Hui Guo, Zina Itkin, et al. (+7)
40 [GO] 2021―Jul―14 Optimization of Triarylpyridinone Inhibitors of the Main Protease of SARS-CoV-2 to Low-Nanomolar Antiviral Potency Chun-Hui Zhang, Krasimir A. Spasov, Raquel A. Reilly, Klarissa Hollander, Elizabeth A. Stone, Joseph A. Ippolito, et al. (+10)
41 [GO] 2021―Jun―09 Potent SARS-CoV-2 mRNA Cap Methyltransferase Inhibitors by Bioisosteric Replacement of Methionine in SAM Cosubstrate Olga Bobiļeva, Raitis Bobrovs, Iveta Kaņepe, Liene Patetko, Gints Kalniņš, Mihails Šišovs, et al. (+8)
42 [GO] 2021―May―27 Molecular Biology Clues Portray SARS-CoV-2 as a Gain-of-Function Laboratory Manipulation of Bat CoV RaTG13 Ariel Fernández
43 [GO] 2021―Mar―29 Intriguing Antiviral Modified Nucleosides: A Retrospective View into the Future Treatment of COVID-19 Ei-ichi Ami, Hiroshi Ohrui
44 [GO] 2021―Mar―17 Structural Insights into Plasticity and Discovery of Remdesivir Metabolite GS-441524 Binding in SARS-CoV-2 Macrodomain Xiaomin Ni, Martin Schröder, Vincent Olieric, May E. Sharpe, Victor Hernandez-Olmos, Ewgenij Proschak, et al. (+3)
45 [GO] 2020―Dec―10 Influence of 4′-Substitution on the Activity of Gemcitabine and Its ProTide Against VZV and SARS-CoV-2 Zihua Zheng, Elisabetta Groaz, Robert Snoeck, Steven De Jonghe, Piet Herdewijn, Graciela Andrei
46 [GO] 2020―Nov―12 Targeted Disassembling of SARS-CoV-2 as It Gets Ready for Cell Penetration Ariel Fernández
47 [GO] 2020―Oct―25 Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2 Mohammad M. Ghahremanpour, Julian Tirado-Rives, Maya Deshmukh, Joseph A. Ippolito, Chun-Hui Zhang, Israel Cabeza de Vaca, et al. (+3)
48 [GO] 2020―Aug―17 Structural Impact of Mutation D614G in SARS-CoV-2 Spike Protein: Enhanced Infectivity and Therapeutic Opportunity Ariel Fernández
49 [GO] 2020―Aug―10 Striking Similarities between CDRs in Some mAbs That Neutralize COVID-19 Tianxiong Mi, Kevin Burgess
50 [GO] 2020―Jun―23 Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment Victoria C. Yan, Florian L. Muller
51 [GO] 2020―May―18 Blocking Coronavirus 19 Infection via the SARS-CoV-2 Spike Protein: Initial Steps Jonathan Whisenant, Kevin Burgess
52 [GO] 2020―May―08 A Role for Metal-Based Drugs in Fighting Covid-19 Infection? The Case of Auranofin Tiziano Marzo, Luigi Messori
 [1] 

52 Results       Page 1


[de][en]

Last change 2025―Jul―29 14:55:09 UTC

© Daten-Quadrat 2022       Done in 0.004 sec